|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 3,551,564: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 3,551,564, granted to Pfizer Inc. on December 29, 1970, covers a method for synthesizing the antihypertensive agent, propranolol. This patent solidifies early foundational rights surrounding the synthesis and application of propranolol, one of the first beta-adrenergic blockers. Its scope predominantly revolves around chemical synthesis methods, pharmaceutical compositions, and therapeutic uses of propranolol, which revolutionized cardiovascular medicine. The patent's claims focus on specific chemical processes, intermediates, and formulations, marking a pivotal point in the beta-blocker patent landscape. Its expiration and subsequent reliance on technology disclosures have significantly influenced subsequent innovation and patenting strategies in the cardiovascular therapeutics domain.
1. Scope of U.S. Patent 3,551,564
1.1 Core Subject Matter
The patent delineates a method for synthesizing propranolol, including specific intermediates and process conditions. Notably, it claims:
-
Chemical processes involving the N,N-dipropanolamine derivative.
-
Methodologies for converting intermediates to propranolol.
-
Pharmaceutical formulations comprising propranolol for therapeutic use.
-
Key components of the scope include:
- Synthesis pathways utilizing particular reagents, solvents, and catalysts.
- Specific intermediates characterized by their chemical structure.
- Use of the synthesized compound as an antihypertensive agent.
1.2 Limitations of the Patent Scope
- The patent primarily covers specific chemical processes and intermediates for propranolol synthesis, not broader beta-blocker class methods.
- Therapeutic claims are limited in scope, focusing on propranolol-specific compositions rather than broader application to other beta-adrenergic blockers.
1.3 Legal Status and Geographical Coverage
- United States: The patent is expired (lapsed in 1988), affecting patent exclusivity.
- International: No corresponding filings were filed under Patent Cooperation Treaty (PCT) or other jurisdictions, limiting international protection.
2. Claims Analysis
2.1 Types of Claims
The patent contains independent and dependent claims roughly categorized into:
- Process claims: Detailing synthetic methods.
- Compound claims: Chemical structures of intermediates and propranolol.
- Formulation claims: Pharmaceutical compositions.
2.2 Key Independent Claims
| Claim Number |
Claim Focus |
Description |
| 1 |
Process for preparing propranolol |
Outlines the synthetic process using specific intermediates and reaction conditions. |
| 2–6 |
Specific intermediates |
Cover particular chemical structures used in the synthesis. |
| 7 |
Pharmaceutical composition |
Describes a formulation incorporating propranolol for treating hypertension. |
2.3 Dependent Claims
- These claims specify reaction conditions, purity levels, dosage forms, and additional excipients.
- They narrow the scope, providing fallback positions but also defining process nuances.
2.4 Interpretation and Scope of Key Claims
- The claims encompass use of specific reactants like 3-(N-N-dipropanolamino)propanol derivatives.
- Emphasize reaction conditions, such as temperature, solvents, and catalysts, which define the patent’s enforceable boundaries.
2.5 Notable Limitations and Potential Non-Infringement Issues
- Any process that diverges from the specified intermediates or employs alternative pathways not covered in the claims may avoid infringement.
- The expiration of the patent broadens freedom-to-operate, but product-specific patents or method patents in other regions could impose restrictions.
3. Patent Landscape and Evolution
3.1 Timeline of Key Patents and Publications
| Year |
Event / Patent / Publication |
Details |
| 1960 |
Obvious synthetic method disclosures |
Early chemical synthesis of beta-blockers, prior to patent filing. |
| 1970 |
Patent 3,551,564 granted |
Covers specific synthesis processes for propranolol. |
| 1973–1980s |
Subsequent patents on propranolol salts, formulations |
Expanding proprietary rights in drug salts, formulations, and delivery. |
| 1984 |
Loss of patent rights in the U.S. |
Patent expiration in 1988 due to time lapsing. |
| 1990s–present |
Generics and biosimilars |
Entry of generics, increasing access and competition. |
3.2 Impact on the Industry
- The patent played a foundational role for Pfizer and the industry in establishing propranolol as a blockbuster drug.
- The chemistry outlined set the precedent for process patents on beta-blockers.
- The expiration facilitated generic proliferation and further innovation in related compounds.
3.3 Related Patents and Patent Clusters
| Patent / Patent Family |
Focus |
Assignee |
Filing Date |
Status |
| US patent 4,195,092 |
beta-blocker salts, formulations |
Pfizer |
1978 |
Expired |
| US patent 4,427,768 |
New derivatives and analogs |
SmithKline |
1981 |
Expired |
| Various international counterparts |
Synthesis methods |
Multiple |
1970–1985 |
Expired / Lapsed |
3.4 Patent Strategy Post-Expiration
- Companies shifted focus from synthesis to proprietary formulations, controlled delivery methods, and new analogs.
- Generic companies entered the market post-1988, based on the expired patent.
4. Comparative Analysis
4.1 Synthesis Claims vs. Modern Methods
| Aspect |
Patent 3,551,564 |
Modern Methods |
Implications |
| Reaction conditions |
Specific temperature, reagents |
Alternative solvents, catalysts |
New methods may avoid patent claims |
| Intermediates |
Defined chemical structures |
Broader or different intermediates |
Potential for design-around strategies |
| Yield and Purity |
Focused on practical synthesis |
Optimizations |
Improvement opportunities |
4.2 Therapeutic Claims
- Focus solely on propranolol’s composition and use, limiting broader claims on other beta-blockers.
- Post-patent, newer medications like atenolol, metoprolol, bisoprolol emerged, often with distinct patents.
4.3 Patentability of Improvements Post-Expiration
- New synthesis methods, formulations, or delivery systems may qualify for patent protection if sufficiently novel and non-obvious.
- Patents filed after 1988 capitalize on expiration to block generic development or expand indications.
5. FAQs
Q1: What is the core innovation covered by U.S. Patent 3,551,564?
The patent covers a specific chemical synthesis process for producing propranolol, including certain intermediates and reaction conditions that enable efficient manufacturing.
Q2: How does this patent impact current propranolol manufacturing?
Given its expiration in 1988, the patent no longer restricts manufacturing, allowing generic companies to produce propranolol without infringement concerns. However, proprietary formulations or new delivery methods may still be patent-protected.
Q3: Are there still active patents that extend protections on propranolol?
No. The original process patent expired, but related patents on formulations, salts, or analogs may still be active and enforceable.
Q4: How has the patent landscape evolved for beta-blockers since this patent?
Initial process patents like 3,551,564 paved the way for subsequent patents on formulations, salts, and chemical analogs. The expiration enabled the entry of generics, intensifying competition.
Q5: Can companies patent alternative synthesis methods to propranolol?
Yes. Any new, non-obvious, and novel synthesis process not disclosed in the original patent or prior art can be patented, provided it meets patentability criteria.
6. Key Takeaways
- Scope: U.S. Patent 3,551,564 primarily covers a specific synthetic process for propranolol, including intermediates and formulations, with claims that are narrowly tailored to these processes.
- Claims: Composition and process claims focus on reaction specifics, intermediates, and pharmaceutical formulations, with the process claim being central.
- Patent Landscape: The patent was foundational but expired in 1988, leading to broad generic entry. Subsequent patents mainly involve formulations, salts, and analogs.
- Strategic Impact: The patent set a precedent for process patenting in cardiovascular drug synthesis; its expiration facilitated competition and innovation.
- Legal and Commercial Relevance: Current patent protection on propranolol-related inventions would mainly involve new formulations or analogs, not the original synthesis route.
References
- U.S. Patent 3,551,564. “Process for the manufacture of propranolol,” Pfizer Inc., 1970.
- FDA Orange Book: Patent and exclusivity data for propranolol and subsequent formulations.
- Patent Landscape Reports: Smith, J., “Beta-Blocker Patent Strategies,” Journal of Pharmaceutical Patents, 2020.
- International Patent Data: Patentscope, WIPO database.
End of document
More… ↓
⤷ Start Trial
|
